SCHEMBL3310488

SCHEMBL3310488

COc1cc(CN(C)C(C)=O)c(-c2ccc[nH]c2=O)cc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP3A4 P08684 4/20 0.39
GAA P10253 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
CRHBP P24387 1/20 0.34
CRHR2 Q13324 1/20 0.34
IMPDH2 P12268 1/20 0.34
IMPDH1 P20839 1/20 0.34
CYP1A1 P04798 1/20 0.34
PDK2 Q15119 1/20 0.33
HTR2A P28223 1/20 0.33
HSD17B1 P14061 1/20 0.33
HSD17B2 P37059 1/20 0.33
ERBB2 P04626 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32
ROCK2 O75116 1/20 0.32
ROCK1 Q13464 1/20 0.32
ALDH1A1 P00352 1/20 0.32
KDM4E B2RXH2 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3309863 0.88 ROCK2 (0.41) CYP3A4TDP1MEN1KMT2ACRHBP
SCHEMBL3312739 0.86 KMT2A (0.41) CYP3A4GAAMEN1KMT2AALDH1A1
SCHEMBL11958301 0.86 CYP3A4 (0.41) CYP3A4GAAIMPDH2IMPDH1CYP1A1
SCHEMBL2363467 0.83 CYP3A4 (0.43) CYP3A4GAAMEN1KMT2AIMPDH2
SCHEMBL3314215 0.83 CYP3A4 (0.45) CYP3A4IMPDH2IMPDH1CYP1A1HTR2A
SCHEMBL2354510 0.83 CYP3A4 (0.41) CYP3A4GAAIMPDH2IMPDH1CYP1A1
SCHEMBL3308176 0.82 CYP3A4 (0.42) CYP3A4GAAMEN1KMT2AIMPDH2
SCHEMBL2364691 0.82 ICMT (0.44) CYP3A4IMPDH2IMPDH1CYP1A1HTR2A
SCHEMBL2362428 0.81 CYP3A4 (0.44) CYP3A4GAATDP1MEN1KMT2A
SCHEMBL2363082 0.81 HTR2A (0.44) CYP3A4GAAIMPDH2IMPDH1CYP1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8232271-B2 Heterocyclic antiviral compounds ROCHE PALO ALTO LLC (US) 2012-07-31 US claimed
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS ROCHE PALO ALTO LLC 2010-05-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100111900-A1 HETEROCYCLIC ANTIVIRAL COMPOUNDS POLR2A, EIF2AK2, POLR2B CYP3A4 423/4885GAA 2099/4885TDP1 2980/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.